BACKGROUND: Mimotopes are peptides mimicking protein, carbohydrates or lipid epitopes and can be generated by phage display technology. When selected by antibodies, they represent exclusively B-cell epitopes and are devoid of antigen/allergen-specific T-cell epitopes. Coupled to carriers or presented in a multiple antigenic peptide form mimotopes achieve immunogenicity and induce epitope-specific antibody responses upon vaccination. OBJECTIVE/ METHODS: In allergy IgG antibodies may block IgE binding to allergens, whereas other IgG antibody specificities enhance this and support the anaphylactic reaction. In cancer, inhibitory antibody specificities prevent growth signals derived from overexpressed oncogenes, whereas growth-promoting specificities enhance signalling and proliferation. Therefore, the mimotope concept is applicable to both fields for epitope-specific vaccination and analysis of conformational B-cell epitopes for the allergen/antigen. RESULTS/ CONCLUSIONS: Mimotope technology is a relatively young theme in allergology and oncology. Still, proof of concept studies testing allergen and tumour mimotope vaccines suggest that mimotopes are ready for clinical trials.
BACKGROUND: Mimotopes are peptides mimicking protein, carbohydrates or lipid epitopes and can be generated by phage display technology. When selected by antibodies, they represent exclusively B-cell epitopes and are devoid of antigen/allergen-specific T-cell epitopes. Coupled to carriers or presented in a multiple antigenic peptide form mimotopes achieve immunogenicity and induce epitope-specific antibody responses upon vaccination. OBJECTIVE/ METHODS: In allergyIgG antibodies may block IgE binding to allergens, whereas other IgG antibody specificities enhance this and support the anaphylactic reaction. In cancer, inhibitory antibody specificities prevent growth signals derived from overexpressed oncogenes, whereas growth-promoting specificities enhance signalling and proliferation. Therefore, the mimotope concept is applicable to both fields for epitope-specific vaccination and analysis of conformational B-cell epitopes for the allergen/antigen. RESULTS/ CONCLUSIONS: Mimotope technology is a relatively young theme in allergology and oncology. Still, proof of concept studies testing allergen and tumour mimotope vaccines suggest that mimotopes are ready for clinical trials.
Authors: S R Durham; S M Walker; E M Varga; M R Jacobson; F O'Brien; W Noble; S J Till; Q A Hamid; K T Nouri-Aria Journal: N Engl J Med Date: 1999-08-12 Impact factor: 91.245
Authors: Joanna Jasinska; Stefan Wagner; Christian Radauer; Roland Sedivy; Thomas Brodowicz; Christoph Wiltschke; Heimo Breiteneder; Hubert Pehamberger; Otto Scheiner; Ursula Wiedermann; Christoph C Zielinski Journal: Int J Cancer Date: 2003-12-20 Impact factor: 7.396
Authors: Nicki Yh Leung; Christine Yy Wai; Marco Hk Ho; Ruiwu Liu; Kit S Lam; Jin Jun Wang; Shang An Shu; Ka Hou Chu; Patrick Sc Leung Journal: Cell Mol Immunol Date: 2015-09-14 Impact factor: 11.530
Authors: Franca Maria Tuccillo; Camillo Palmieri; Giuseppe Fiume; Annamaria de Laurentiis; Marco Schiavone; Cristina Falcone; Enrico Iaccino; Ricciarda Galandrini; Cristina Capuano; Angela Santoni; Francesco Paolo D'Armiento; Claudio Arra; Antonio Barbieri; Fabrizio Dal Piaz; David Venzon; Patrizia Bonelli; Franco Maria Buonaguro; Iris Scala; Massimo Mallardo; Ileana Quinto; Giuseppe Scala Journal: Mol Cancer Ther Date: 2013-12-19 Impact factor: 6.261
Authors: M Muralidhar Reddy; Rosemary Wilson; Johnnie Wilson; Steven Connell; Anne Gocke; Linda Hynan; Dwight German; Thomas Kodadek Journal: Cell Date: 2011-01-07 Impact factor: 41.582
Authors: Andrea Havasi; Weining Lu; Herbert T Cohen; Laurence Beck; Zhiyong Wang; Chinaemare Igwebuike; Steven C Borkan Journal: Am J Physiol Renal Physiol Date: 2016-09-21
Authors: Yong He; Yonggang Wang; Evi B Struble; Pei Zhang; Soma Chowdhury; Jennifer L Reed; Michael Kennedy; Dorothy E Scott; Robert W Fisher Journal: Virol J Date: 2012-09-24 Impact factor: 4.099